Medicine and Dentistry
Liver Transplantation
100%
Hepatocellular Carcinoma
87%
Overall Survival
42%
Surgeon
39%
Neoplasm
37%
Surgery
31%
Kidney Transplantation
29%
Liver Graft
27%
Cholangiocarcinoma
27%
Hepatectomy
24%
Odds Ratio
18%
Weakness
18%
Liver Tumor
18%
Thromboelastography
18%
Hepatobiliary Surgery
18%
Pancreas Adenocarcinoma
18%
Radioembolization
18%
Yttrium 90
18%
Biliary Tract Surgery
17%
Recurrent Disease
15%
Transplantation
14%
Graft Survival
14%
Pediatrics
13%
Disease
13%
Organ Transplantation
12%
General Surgery
11%
Patient Selection
10%
Fluid Resuscitation
10%
Survival Rate
10%
Allograft
9%
Chemoprophylaxis
9%
Interventional Radiology
9%
Cancer Stem Cell
9%
Heparin
9%
Gemcitabine
9%
Cardiovascular System
9%
Quality Improvement
9%
Colectomy
9%
Preoperative Chemotherapy
9%
Adjuvant Therapy
9%
Graft Versus Host Reaction
9%
Chemoradiotherapy
9%
Solid Organ Transplantation
9%
DNA Methyltransferase 3A
9%
Flexibility
9%
Cancer Registry
9%
Malignant Neoplasm
9%
Health Care Cost
9%
Decompensated Liver Cirrhosis
9%
Hypercoagulability
9%
Keyphrases
Liver Transplantation
18%
BCLC Staging
18%
FH535
18%
Hepatocellular Carcinoma
12%
Kidney Transplantation
11%
Hepatobiliary Surgery
10%
Hepatocellular Carcinoma Cancer
10%
Combined Hepatocellular-cholangiocarcinoma
9%
Signaling Pathway
9%
General Surgery Residents
9%
Interventional Radiology
9%
Hepatobiliary
9%
Catenin
9%
Delphi Consensus
9%
Clonal Hematopoiesis of Indeterminate Potential
9%
Bone Marrow Failure
9%
Autologous Vein
9%
Cadaveric
9%
Controlled Donation after Circulatory Death
9%
Circulatory Death Donors
9%
Surgery Curriculum
9%
Liver Cancer Stem Cells
9%
Yttrium-90 Radioembolization
9%
Unplanned Readmission
9%
Donor Nephrectomy
9%
Postoperative Venous Thromboembolism
9%
Venous Reconstruction
9%
UCSF Criteria
9%
National Review
9%
Hepatopancreatobiliary
9%
Graft-versus-host Disease (GvHD)
9%
Split Liver Transplantation
9%
Cell Carcinoma
9%
Hemophagocytosis
9%
Cardiovascular Radiology
9%
Pediatric Kidney Transplantation
9%
Patency
9%
DNMT3A mutation
9%
Hepatocellular Carcinoma Cells
9%
Single Center
9%
Center Volume
9%
Hepatocellular Cholangiocarcinoma
9%
Donor-derived Cell-free DNA
9%
Transplant Referral
9%
Single-center Study
9%
Kidney Allograft Survival
9%
Black Men
9%
Primary Repair
7%
Solitary Hepatocellular Carcinoma
7%
Marrow
6%
Pharmacology, Toxicology and Pharmaceutical Science
Liver Cell Carcinoma
45%
Catenin
18%
Liver Cancer
18%
End Stage Liver Disease
13%
Liver Cirrhosis
9%
Gemcitabine
9%
Paclitaxel
9%
Chemoradiation Therapy
9%
Bile Duct Carcinoma
9%
Pancreas Adenocarcinoma
9%
Kidney Failure
9%
Chemotherapy
9%
Sorafenib
9%
Neoplasm
7%
Overall Survival
5%
Survival Rate
5%